John Murphy, M.D., MPH, DPH, President The Covid-19 Long-haul Foundation
Abstract
Motor neuron diseases (MNDs) comprise a heterogeneous spectrum of neurodegenerative and immune-mediated disorders characterized by selective vulnerability of upper and/or lower motor neurons, culminating in progressive weakness, muscle atrophy, and disability. Amyotrophic lateral sclerosis (ALS) represents the prototypical and most prevalent entity, but the spectrum extends to primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), spinal muscular atrophies (SMAs), hereditary spastic paraplegias (HSPs), and a range of overlap and mimic syndromes. Over the past three decades, advances in molecular genetics, neuropathology, and neurophysiology have reframed MND not as a single disease but as a continuum of clinicopathologic phenotypes unified by convergent mechanisms of neuronal vulnerability. This review synthesizes current understanding of MND etiology, pathology, and physiology; outlines contemporary diagnostic frameworks; examines disease progression and epidemiology; and discusses outcomes in light of evolving therapeutic strategies.
Introduction
Motor neuron diseases occupy a unique position within neurology, defined not by a single lesion or pathway but by the selective degeneration of neurons that govern voluntary movement. The motor system’s hierarchical architecture—upper motor neurons (UMNs) within the motor cortex and corticospinal tracts, and lower motor neurons (LMNs) within the brainstem and spinal cord—permits a range of clinical phenotypes depending on the anatomical distribution and tempo of neuronal loss.
Historically, ALS was considered synonymous with MND. However, clinicopathologic and genetic insights have revealed substantial overlap among entities once considered discrete. The modern conception of MND is therefore spectrum-based, integrating ALS with phenotypes dominated by UMN involvement (PLS), LMN involvement (PMA), childhood-onset genetic disorders (SMAs), and complex hereditary syndromes involving both motor and extramotor systems.
This spectrum approach has practical implications. It influences diagnostic criteria, prognostication, trial design, and the interpretation of emerging therapies. It also underscores the need for precision medicine in disorders once viewed as uniformly fatal and therapeutically barren.
Classification of the Motor Neuron Disease Spectrum
Amyotrophic Lateral Sclerosis
ALS is characterized by the combined degeneration of UMNs and LMNs, leading to progressive weakness, muscle wasting, spasticity, and ultimately respiratory failure. Bulbar involvement—manifesting as dysarthria and dysphagia—is common and prognostically significant.
Primary Lateral Sclerosis
PLS is defined by slowly progressive UMN degeneration without significant LMN involvement for prolonged periods. Although traditionally considered benign relative to ALS, long-term disability can be substantial.
Progressive Muscular Atrophy
PMA is marked by isolated LMN degeneration. Once viewed as a distinct entity, PMA is now often considered part of the ALS continuum, as many patients eventually develop UMN signs.
Spinal Muscular Atrophies
SMAs encompass a group of genetic disorders caused primarily by SMN1 gene deficiency, leading to LMN loss. Although mechanistically distinct from ALS, they share downstream pathways of neuronal degeneration.
Hereditary Spastic Paraplegias and Overlap Syndromes
HSPs primarily affect UMNs but increasingly are recognized to overlap genetically and pathologically with ALS, particularly in complex forms with additional neurologic features.
Etiology
Genetic Contributions
Approximately 10–15% of ALS cases are familial, with mutations identified in genes including SOD1, C9orf72, TARDBP, and FUS. These genes implicate pathways involving protein homeostasis, RNA metabolism, and nucleocytoplasmic transport. Even in sporadic disease, genetic risk factors contribute to susceptibility and phenotype expression.
Environmental and Lifestyle Factors
Epidemiologic studies have associated ALS risk with military service, exposure to pesticides and heavy metals, head trauma, and intense physical exertion. These associations are modest but suggest gene–environment interactions.
Post-Infectious and Immune Mechanisms
Viral infections, including enteroviruses and more recently SARS-CoV-2, have been proposed as triggers that unmask latent vulnerability through immune activation, neuroinflammation, or metabolic stress. While causality remains unproven, post-infectious onset patterns warrant mechanistic investigation.
Pathology
Neuronal Degeneration
The pathological hallmark of ALS and related disorders is the loss of motor neurons accompanied by gliosis. In ALS, cytoplasmic inclusions containing TDP-43 are present in the majority of cases, linking protein misfolding to neuronal death.
Corticospinal Tract Degeneration
Degeneration of descending motor pathways contributes to spasticity and hyperreflexia. Pathologic changes include axonal loss and myelin degeneration.
Extramotor Involvement
Contrary to earlier dogma, ALS frequently involves non-motor regions, including frontal and temporal cortices, accounting for cognitive and behavioral impairment in a substantial subset of patients.
Physiology and Pathophysiology
Excitotoxicity
Glutamate-mediated excitotoxicity, driven by impaired astrocytic uptake, results in excessive calcium influx and neuronal injury.
Mitochondrial Dysfunction
Mitochondrial abnormalities impair energy metabolism, increase oxidative stress, and sensitize neurons to apoptosis.
Axonal Transport Failure
Defects in microtubule-based transport disrupt delivery of essential proteins and organelles to distal axons, particularly in long motor neurons.
Neuroinflammation
Microglial activation and astrocytic dysfunction contribute to a toxic neuronal environment, shifting from protective to deleterious roles as disease progresses.
Clinical Diagnosis
Symptomatology
Initial symptoms often include focal weakness, muscle cramps, and fasciculations. Bulbar symptoms may precede limb involvement or arise later in the disease course.
Neurologic Examination
The coexistence of UMN and LMN signs in multiple body regions remains central to diagnosis. However, early disease may present with incomplete features.
Electrodiagnostic Studies
Electromyography demonstrates active and chronic denervation, supporting LMN involvement and excluding mimics.
Neuroimaging and Laboratory Testing
MRI and targeted laboratory studies are essential to exclude structural, inflammatory, metabolic, and infectious mimics.
Diagnostic Criteria
Revised El Escorial, Awaji, and Gold Coast criteria reflect evolving efforts to balance diagnostic sensitivity with specificity, particularly for early disease.
Disease Progression
Patterns of Spread
Disease typically spreads contiguously from an initial focal region, though multifocal onset occurs. Rate of progression varies widely.
Bulbar and Respiratory Involvement
Bulbar dysfunction and respiratory muscle weakness are major determinants of morbidity and mortality.
Cognitive and Behavioral Decline
Frontotemporal dysfunction affects survival, caregiver burden, and decision-making capacity.
Epidemiology
ALS incidence ranges from 1.5 to 2.5 cases per 100,000 person-years in Western populations, with prevalence increasing due to improved survival. Peak onset occurs between ages 55 and 75, with a modest male predominance. Geographic clustering and temporal trends support multifactorial causation.
Outcomes and Prognosis
Median survival in ALS is approximately three to five years from symptom onset, though substantial heterogeneity exists. Favorable prognostic factors include younger age at onset, limb-onset disease, and slower early progression. Advances in multidisciplinary care, noninvasive ventilation, and disease-modifying therapies have incrementally improved survival and quality of life.
Therapeutic Landscape and Future Directions
Current disease-modifying treatments modestly slow progression. Gene-targeted therapies, antisense oligonucleotides, and immunomodulatory strategies represent promising avenues. Biomarker development, including neurofilament measurements, is transforming diagnosis and trial design.
Conclusion
Motor neuron diseases represent a biologically and clinically diverse spectrum unified by selective neuronal vulnerability and convergent pathogenic mechanisms. The spectrum framework has reshaped understanding of these disorders, emphasizing continuity rather than categorical separation. Continued integration of molecular biology, clinical neurology, and systems neuroscience offers the best prospect for altering outcomes in diseases long regarded as inexorable.
References
- Brown RH Jr, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–172.
- Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
- Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–955.
- Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197–206.
- van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–2098.
- Saberi S, Stauffer JE, Schulte DJ, et al. Neuropathology of amyotrophic lateral sclerosis and related disorders. Neurol Clin. 2015;33:855–876.
- Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in ALS and FTLD. Science. 2006;314:130–133.
- Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17–23.
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in C9orf72. Neuron. 2011;72:245–256.
- Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis. Lancet Neurol. 2017;16:689–700.
- Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688–1700.
- Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–299.
- de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for ALS. Clin Neurophysiol. 2008;119:497–503.
- Shefner JM, Al-Chalabi A, Baker MR, et al. Gold Coast diagnostic criteria. Lancet Neurol. 2020;19:976–986.
- Turner MR, Grosskreutz J, Kassubek J, et al. Towards a neuroimaging biomarker for ALS. Lancet Neurol. 2011;10:400–403.
- Strong MJ, Abrahams S, Goldstein LH, et al. ALS–frontotemporal spectrum disorder. Lancet Neurol. 2017;16:1007–1019.
- Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9orf72. Neuron. 2011;72:257–268.
- Boillée S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39–59.
- Ilieva H, Polymenidou M, Cleveland DW. Non–cell autonomous toxicity in ALS. Cell. 2009;136:1068–1081.
- Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig. Nature. 2001;411:337–341.
- Talbot K, Tizzano EF. The clinical landscape for SMA. Nat Rev Neurol. 2017;13:637–648.
- Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.
- Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS. Lancet Neurol. 2009;8:558–567.
- Benatar M, Wuu J. Presymptomatic studies in ALS. Lancet Neurol. 2012;11:933–942.
- Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in ALS. Lancet Neurol. 2019;18:126–137.